Latest News
Biogen Announces Results from the Phase 2/3 DEVOTE Study
Today, Biogen announced the publication of results from the pivotal Phase 2/3 DEVOTE study in Nature Medicine, highlighting the potential benefits of a high-dose regimen of nusinersen for people living […]
SMA Community Research and Legislative Priorities Finalized in New Federal Law
On February 3rd, Congress approved and the President signed into law key research and legislative priorities that Cure SMA and individuals with spinal muscular atrophy (SMA) and their families have […]
Genentech Releases Winter SMA Community Update Letter
Genentech recently released an update on their continued collaboration with the SMA community and Evrysdi® tablet updates. They will continue to provide timely updates as they become available. Read the […]
All 2026 Walk-n-Roll Events Are Open
Cure SMA warmly invites you to join us at one of our 2026 Walk-n-Roll events-where community meets impact! This year, you can register and start fundraising for both spring and […]
Cure SMA Advocacy Highlights of 2025
Thank you to the individuals with spinal muscular atrophy (SMA), their family members, and other supporters who helped advocate for SMA community priorities in 2025. As the year comes to […]
Together, We’re Changing the Story of SMA
Watch the video and see how far we’ve come and the future we’re building together. Donate to Support the SMA Community Your support accelerates research, strengthens advocacy, and expands critical […]